Howard Dicks James, McCann Lucy Jane, Tolley Abraham, Barrell Alice, Johnson Lucy, Kuhn Isla, Ford John
School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Pediatr Diabetes. 2025 Jun 3;2025:8875203. doi: 10.1155/pedi/8875203. eCollection 2025.
Socioeconomic status (SES) and ethnic inequalities in type 1 diabetes (T1D) outcomes are well-established. There is concern that unequal access to technologies, including continuous glucose monitoring (CGM), may increase disparities. This systematic review summarises the evidence for inequalities in the prevalence of CGM use for children and young people (CYP) and outcomes for CGM users. Medline, Embase and Web of Science were searched for observational studies published between January 2020 and July 2023 which report CGM use stratified by any PROGRESS-Plus criteria for T1D patients under 26. Reports based in low- or middle-income countries, ≤500 participants or only reporting hybrid closed-loop systems were excluded. Primary outcomes were the proportion of patients using CGM and HbA1c of CGM users. Quality assessment was performed using the Newcastle-Ottawa Scale. Unadjusted odds ratios were calculated from the extracted summary data, though heterogeneity precluded meta-analysis. The protocol was preregistered with PROSPERO (CRD42023438139). Of the 3369 unique studies identified, 27 met the inclusion criteria. Thirty-three percent were of 'good' or 'very good' quality. We found decreased CGM use and higher discontinuation for low SES, low education, publicly insured and minority ethnic, especially Black, CYP. These associations were generally robust to adjustment for other sociodemographic variables, suggesting an independent effect. Lower SES inequalities were seen in countries where CGM is reimbursed. Although low SES and minority ethnicity were associated with poorer outcomes in general, for CGM users there was no significant association between domains of disadvantage and higher HbA1c, excepting parental education. There are significant SES, ethnic and education inequalities in CGM use for CYP with T1D, particularly when reimbursement is limited. This inequity is contributing to inequalities in T1D outcomes. However, evidence suggests CYP benefit equally from CGM use, irrespective of ethnicity and SES. Increasing CGM funding and use is likely to reduce outcome inequalities.
1型糖尿病(T1D)结局中的社会经济地位(SES)和种族不平等现象已得到充分证实。人们担心,包括持续葡萄糖监测(CGM)在内的技术获取不平等可能会加剧差异。本系统综述总结了儿童和青少年(CYP)使用CGM的患病率不平等以及CGM使用者结局方面的证据。检索了Medline、Embase和科学网,查找2020年1月至2023年7月期间发表的观察性研究,这些研究报告了按任何PROGRESS-Plus标准分层的26岁以下T1D患者的CGM使用情况。排除了来自低收入或中等收入国家、参与者≤500或仅报告混合闭环系统的报告。主要结局是使用CGM的患者比例和CGM使用者的糖化血红蛋白(HbA1c)。使用纽卡斯尔-渥太华量表进行质量评估。从提取的汇总数据中计算未调整的比值比,尽管异质性排除了进行荟萃分析的可能性。该方案已在PROSPERO(CRD42023438139)上预先注册。在确定的3369项独特研究中,27项符合纳入标准。33%的研究质量为“良好”或“非常良好”。我们发现,社会经济地位低、教育程度低、有公共保险的人群以及少数族裔,尤其是黑人青少年,使用CGM的比例降低,停药率更高。在对其他社会人口学变量进行调整后,这些关联通常仍然很显著,表明存在独立影响。在CGM得到报销的国家,社会经济地位较低导致的不平等现象较少。虽然总体而言,社会经济地位低和少数族裔与较差的结局相关,但对于CGM使用者来说,除了父母教育程度外,不利因素领域与较高的糖化血红蛋白之间没有显著关联。对于患有T1D的青少年,在CGM使用方面存在显著的社会经济地位、种族和教育不平等,尤其是在报销有限的情况下。这种不平等正在导致T1D结局的不平等。然而,有证据表明,无论种族和社会经济地位如何,青少年从CGM使用中获得的益处是相同的。增加CGM资金投入和使用可能会减少结局不平等。